
Semaglutide cuts BMI 13.5% in children aged 6 to 11 with obesity
Key Takeaways
- In STEP Young, semaglutide plus lifestyle counseling reduced BMI by 13.5% vs a 2.7% increase with placebo at 68 weeks in children aged 6 to <12 years, the trial's primary analysis.
- The widely cited "nearly 80% achieved ≥10% BMI reduction" figure comes from an efficacy-estimand, multiplicity-unadjusted supportive end point and should be interpreted cautiously.
In STEP Young, semaglutide cut BMI 13.5% at 68 weeks vs a 2.7% rise with placebo in children aged 6 to <12 years with obesity.
Once-weekly semaglutide, added to lifestyle counseling, produced a significantly greater reduction in body mass index (BMI) than placebo in children aged 6 to younger than 12 years with obesity, according to results of the phase 3 STEP Young trial published in The New England Journal of Medicine.¹ At week 68, mean BMI fell 13.5% with semaglutide and rose 2.7% with placebo, an estimated between-group difference of –16.2 percentage points (95% CI, –19.4 to –12.9; P < .001).¹ Data were also presented at ObesityWeek 2026.²
"Severe obesity can profoundly affect a child's physical health, emotional well-being, and daily life," said lead author Ania M. Jastreboff, MD, PhD, professor of medicine (endocrinology) and pediatrics (pediatric endocrinology) at Yale School of Medicine and director of the Yale Obesity Research Center.² She added that treatment "was accompanied by improvements in multiple cardiometabolic measures."²
STEP Young trial design and semaglutide efficacy in children aged 6 to 11
The double-blind, multinational trial randomly assigned 167 children 2:1 to once-weekly subcutaneous semaglutide (n = 112) or placebo (n = 55) for 104 weeks, followed by a 7-week off-drug washout.¹ Both groups received lifestyle counseling.¹ The maximum dose was 2.4 mg for children weighing more than 60 kg at baseline and 1.7 mg for those weighing 45 to 60 kg, or the maximum tolerated dose.² More than 85% of participants had class II or III obesity at baseline.²
The primary endpoint was percent change in BMI from baseline to week 68; the confirmatory secondary endpoint was a reduction in BMI category.¹ At week 68, 79% of children receiving semaglutide moved to a lower BMI category vs 23% receiving placebo (odds ratio, 7.8; 95% CI, 3.5-17.6; P < .001), and 38% vs 2% had a BMI below the 95th percentile for age and sex.¹ At week 104, BMI had changed by –9.4% with semaglutide and +8.4% with placebo (difference, –17.8 percentage points; 95% CI, –22.2 to –13.3).¹
Adverse events occurred in 96% of the semaglutide group and 93% of the placebo group.¹ Gastrointestinal events were most common and more frequent with semaglutide, leading to discontinuation in 1 participant.¹ Novo Nordisk reported that no safety concerns were identified for growth or pubertal development.²
Pediatric obesity burden and current treatment guidance for children under 12
Childhood obesity is associated with type 2 diabetes, dyslipidemia, hypertension, and obstructive sleep apnea.³ The 2023 American Academy of Pediatrics clinical practice guideline recommends offering weight-loss pharmacotherapy to adolescents aged 12 years and older with obesity as an adjunct to intensive health behavior and lifestyle treatment, but pharmacologic options for younger children have been limited.³ Semaglutide is not approved in the United States for patients younger than 12 years.²
GLP-1 receptor agonist background and the STEP TEENS precedent
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved for the treatment of obesity in adults and adolescents.¹ In the STEP TEENS trial, semaglutide 2.4 mg reduced BMI by 16.1% vs a 0.6% rise with placebo at 68 weeks in adolescents with obesity.⁴ Novo Nordisk previously studied liraglutide in the same 6- to younger-than-12-year age group in SCALE Kids.²
Interpreting the STEP Young semaglutide data
The headline figures in the company's release (a 17.4% BMI reduction and a 10% or greater reduction in nearly 80% of children) reflect the efficacy estimand, which assumes all children stayed on treatment.² Several come from supportive endpoints not adjusted for multiplicity, which Novo Nordisk notes should not be used to infer definitive treatment effects.² The prespecified primary analysis, which counts children regardless of adherence, showed the more conservative 13.5% reduction.¹
The treatment effect in younger children was broadly similar in magnitude to that seen in adolescents.¹,⁴ However, BMI reduction with semaglutide narrowed between weeks 68 and 104 under the treatment-regimen analysis, even as the gap vs placebo held.¹
References
Jastreboff AM, Harder-Lauridsen NM, Van Name M, et al; STEP Young Investigators. Semaglutide for the treatment of obesity in children 6 to <12 years of age. N Engl J Med. Published online November 16, 2026. doi:10.1056/NEJMoa2604058
Wegovy resulted in a BMI reduction of 10% or more in almost 80% of children with obesity aged 6 to under 12, compared to 0% with placebo in STEP Young trial, published in The New England Journal of Medicine. News release. Novo Nordisk Inc. November 16, 2026. Accessed November 16, 2026.
https://www.prnewswire.com/news-releases/wegovy-resulted-in-a-bmi-reduction-of-10-or-more-in-almost-80-of-children-with-obesity-aged-6-to-under-12-compared-to-0-with-placebo-in-step-young-trial-published-in-the-new-england-journal-of-medicine-302940442.html Hampl SE, Hassink SG, Skinner AC, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023;151(2):e2022060640. doi:10.1542/peds.2022-060640
Weghuber D, Barrett T, Barrientos-Pérez M, et al; STEP TEENS Investigators. Once-weekly semaglutide in adolescents with obesity. N Engl J Med. 2022;387(24):2245-2257. doi:10.1056/NEJMoa2208601
Related to this article








